Skip to main content
. 2023 Oct 13;13(1):157. doi: 10.1038/s41408-023-00930-7

Fig. 1. Consort diagram of the selection process for identifying patients eligible for the current study.

Fig. 1

DLBCL diffuse large B-cell lymphoma, IPI International Prognostic Index, NCCN-IPI National Comprehensive Cancer Network IPI, LYFO Danish Lymphoma Register, R rituximab, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.